Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?

Richard J. Rodeheffer

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

Elevated plasma brain natriuretic (BNP) concentrations correlate with increased cardiac filling pressures. Therefore, increased BNP has been proposed as a marker for asymptomatic ventricular dysfunction, as an aid in the diagnosis of cardiac dyspnea, as an end point to assess the efficacy of heart failure therapy, and as a prognostic marker in heart failure. An understanding of the utility of BNP requires an appreciation of the sensitivity, specificity, and diagnostic accuracy of BNP in each of these clinical situations. At this time, there is strong evidence for the value of BNP in the evaluation of dyspnea of uncertain cause. Further population studies will need to be performed to refine the application of BNP to community cohorts and to determine its clinical value and cost-effectiveness as a screening tool in the early diagnosis of ventricular dysfunction. To make optimal use of BNP for the assessment of heart failure therapy and prognosis in individual patients, physicians will require additional information on the biological variability of BNP. Studies comparing the sensitivity, specificity, and predictive value of the available BNP and N-terminal pro-BNP assays need to be conducted in each of these clinical settings.

Original languageEnglish (US)
Pages (from-to)740-749
Number of pages10
JournalJournal of the American College of Cardiology
Volume44
Issue number4
DOIs
StatePublished - Aug 18 2004

Fingerprint

Brain Natriuretic Peptide
Ventricular Dysfunction
Heart Failure
Dyspnea
Sensitivity and Specificity
Cost-Benefit Analysis
Early Diagnosis
Physicians
Pressure
Brain
Therapeutics
Population

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Measuring plasma B-type natriuretic peptide in heart failure : Good to go in 2004? / Rodeheffer, Richard J.

In: Journal of the American College of Cardiology, Vol. 44, No. 4, 18.08.2004, p. 740-749.

Research output: Contribution to journalArticle

@article{ba93295500ba45e5a5fbd96088bc3f07,
title = "Measuring plasma B-type natriuretic peptide in heart failure: Good to go in 2004?",
abstract = "Elevated plasma brain natriuretic (BNP) concentrations correlate with increased cardiac filling pressures. Therefore, increased BNP has been proposed as a marker for asymptomatic ventricular dysfunction, as an aid in the diagnosis of cardiac dyspnea, as an end point to assess the efficacy of heart failure therapy, and as a prognostic marker in heart failure. An understanding of the utility of BNP requires an appreciation of the sensitivity, specificity, and diagnostic accuracy of BNP in each of these clinical situations. At this time, there is strong evidence for the value of BNP in the evaluation of dyspnea of uncertain cause. Further population studies will need to be performed to refine the application of BNP to community cohorts and to determine its clinical value and cost-effectiveness as a screening tool in the early diagnosis of ventricular dysfunction. To make optimal use of BNP for the assessment of heart failure therapy and prognosis in individual patients, physicians will require additional information on the biological variability of BNP. Studies comparing the sensitivity, specificity, and predictive value of the available BNP and N-terminal pro-BNP assays need to be conducted in each of these clinical settings.",
author = "Rodeheffer, {Richard J.}",
year = "2004",
month = "8",
day = "18",
doi = "10.1016/j.jacc.2004.03.082",
language = "English (US)",
volume = "44",
pages = "740--749",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Measuring plasma B-type natriuretic peptide in heart failure

T2 - Good to go in 2004?

AU - Rodeheffer, Richard J.

PY - 2004/8/18

Y1 - 2004/8/18

N2 - Elevated plasma brain natriuretic (BNP) concentrations correlate with increased cardiac filling pressures. Therefore, increased BNP has been proposed as a marker for asymptomatic ventricular dysfunction, as an aid in the diagnosis of cardiac dyspnea, as an end point to assess the efficacy of heart failure therapy, and as a prognostic marker in heart failure. An understanding of the utility of BNP requires an appreciation of the sensitivity, specificity, and diagnostic accuracy of BNP in each of these clinical situations. At this time, there is strong evidence for the value of BNP in the evaluation of dyspnea of uncertain cause. Further population studies will need to be performed to refine the application of BNP to community cohorts and to determine its clinical value and cost-effectiveness as a screening tool in the early diagnosis of ventricular dysfunction. To make optimal use of BNP for the assessment of heart failure therapy and prognosis in individual patients, physicians will require additional information on the biological variability of BNP. Studies comparing the sensitivity, specificity, and predictive value of the available BNP and N-terminal pro-BNP assays need to be conducted in each of these clinical settings.

AB - Elevated plasma brain natriuretic (BNP) concentrations correlate with increased cardiac filling pressures. Therefore, increased BNP has been proposed as a marker for asymptomatic ventricular dysfunction, as an aid in the diagnosis of cardiac dyspnea, as an end point to assess the efficacy of heart failure therapy, and as a prognostic marker in heart failure. An understanding of the utility of BNP requires an appreciation of the sensitivity, specificity, and diagnostic accuracy of BNP in each of these clinical situations. At this time, there is strong evidence for the value of BNP in the evaluation of dyspnea of uncertain cause. Further population studies will need to be performed to refine the application of BNP to community cohorts and to determine its clinical value and cost-effectiveness as a screening tool in the early diagnosis of ventricular dysfunction. To make optimal use of BNP for the assessment of heart failure therapy and prognosis in individual patients, physicians will require additional information on the biological variability of BNP. Studies comparing the sensitivity, specificity, and predictive value of the available BNP and N-terminal pro-BNP assays need to be conducted in each of these clinical settings.

UR - http://www.scopus.com/inward/record.url?scp=4143068099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4143068099&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2004.03.082

DO - 10.1016/j.jacc.2004.03.082

M3 - Article

C2 - 15312852

AN - SCOPUS:4143068099

VL - 44

SP - 740

EP - 749

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 4

ER -